The Janssen Pharmaceutical Companies of Johnson & Johnson and the Lung Cancer Initiative at Johnson & Johnson are taking on the world's most deadly cancer.

Reiko Akizuki, director of the Oncology Department at Janssen Japan, is seeking collaborators to use Japan’s rich diagnostic pathology and radiology databases to better understand the genomic and molecular foundations of early stage lung lesions.

Click here to read the full article.